Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 15/20 | 0.43 |
| ▸ | LCK | P06239 | 2/20 | 0.37 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.34 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.34 |
| ▸ | PRKCI | P41743 | 3/20 | 0.34 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.32 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20358627 | 1.00 | BTK (0.43) | BTKLCKHDAC4HDAC6PRKCI | |
| SCHEMBL20371826 | 0.86 | PRKCI (0.34) | BTKHDAC6PRKCIHRH4HRH3 | |
| SCHEMBL20359557 | 0.86 | BTK (0.62) | BTKLCKHDAC4HDAC6 | |
| SCHEMBL20358484 | 0.86 | BTK (0.62) | BTKLCKHDAC4HDAC6 | |
| SCHEMBL20359031 | 0.86 | HDAC4 (0.45) | BTKLCKHDAC4HDAC6HRH4 | |
| SCHEMBL20358931 | 0.86 | HDAC4 (0.45) | BTKLCKHDAC4HDAC6HRH4 | |
| SCHEMBL20360083 | 0.86 | BTK (0.62) | BTKLCKHDAC4HDAC6 | |
| SCHEMBL20359418 | 0.86 | BTK (0.46) | BTKLCKHDAC4HDAC6HRH4 | |
| Hydrochloric Acid SCHEMBL20358531 | 0.86 | HDAC4 (0.44) | BTKLCKHDAC4HDAC6HRH4 | |
| SCHEMBL20371828 | 0.86 | BTK (0.43) | BTKLCK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180194762-A1 | PYRAZOLO[3,4-b]PYRIDINE AND PYRROLO[2,3-b]PYRIDINE INHIBITORS OF BRUTON'S TYROSINE KINASE | PHARMACYCLICS LLC (US) | 2018-07-12 | — | — | US | disclosed |
| US-20180194762-A1 | PYRAZOLO[3,4-b]PYRIDINE AND PYRROLO[2,3-b]PYRIDINE INHIBITORS OF BRUTON'S TYROSINE KINASE | PHARMACYCLICS LLC (US) | 2018-07-12 | — | — | US | disclosed |
| US-20180194762-A1 | PYRAZOLO[3,4-b]PYRIDINE AND PYRROLO[2,3-b]PYRIDINE INHIBITORS OF BRUTON'S TYROSINE KINASE | PHARMACYCLICS LLC (US) | 2018-07-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180194762-A1 | PYRAZOLO[3,4-b]PYRIDINE AND PYRROLO[2,3-b]PYRIDINE INHIBITORS OF BRUTON'S TYROSINE KINASE | BTK, SYK, LCK | BTK 1/4885LCK 3/4885HDAC4 2054/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.